Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

A 61-year-old man allegedly stabbed Sunday night by his 26-year-old son in Pearl City told police his son suffers from ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

The results underscore the difficulties in treating schizophrenia, a severe mental illness that can cause people to hear ...

People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

High dropout rates are typical in schizophrenia drug studies. Finding a drug that works can be a long ordeal punctuated by crises and hospitalizations. Side effects of existing medications ...

Many currently available schizophrenia drugs work by blocking dopamine type 2 (D2) receptors. But these drugs offer limited efficacy while introducing side effects that make it hard for patients ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...